An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is a major unmet medical need. Most patients have poor long-term survival, and treatment has not significantly changed in 40 years. Recently, bispecific antibodies that redirect the cytotoxic activity of effector T cells by binding to CD3, the signaling component of the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Leong, Steven R., Sukumaran, Siddharth, Hristopoulos, Maria, Totpal, Klara, Stainton, Shannon, Lu, Elizabeth, Wong, Alfred, Tam, Lucinda, Newman, Robert, Vuillemenot, Brian R., Ellerman, Diego, Gu, Chen, Mathieu, Mary, Dennis, Mark S., Nguyen, Allen, Zheng, Bing, Zhang, Crystal, Lee, Genee, Chu, Yu-Waye, Prell, Rodney A., Lin, Kedan, Laing, Steven T., Polson, Andrew G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5290988/
https://ncbi.nlm.nih.gov/pubmed/27908880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-08-735365
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados